Sherpa Healthcare Partners

Sherpa Healthcare Partners is a Beijing-headquartered venture firm dedicated exclusively to healthcare, with a focus on life technologies and innovative therapeutics. The firm’s specialist healthcare mandate distinguishes it from generalist Chinese venture funds that approach healthcare opportunistically and gives it the depth of expertise needed to underwrite clinical-stage assets and complex therapeutic platforms.

The thesis covers biotech, pharma and therapeutics, and diagnostics, with explicit AI focus across those categories. Sherpa Healthcare Partners invests in clinical-stage therapeutic assets, novel biotech platforms, and AI-enabled diagnostics, often participating in larger syndicated rounds where multiple specialist healthcare investors share clinical and commercial risk. The firm’s positioning suggests deep relationships across the Chinese clinical-stage biotech ecosystem and the international biotech investing community.

The firm writes $5M to $25M checks across Series A, Series B, and Series C, which positions it as an institutional lead or co-lead rather than a seed-stage formation investor. Geographic focus is China, with selective international participation when portfolio companies expand globally or syndicate with international healthcare specialists. Founders raising seed rounds or operating outside the healthcare specialty should look elsewhere.

The team is healthcare-specialist by design, with investors who bring clinical, scientific, and commercial healthcare backgrounds rather than generalist technology investing experience. Specific partner names are not provided in the source data, and founders should engage through Sherpa Healthcare Partners’ main channels.

The approach is healthcare-specialist with syndication discipline. Sherpa Healthcare Partners is comfortable participating in larger rounds alongside other specialist investors and brings serious clinical and scientific diligence to its underwriting. The firm is a strong fit for Chinese clinical-stage biotech and therapeutics founders who want a specialist healthcare investor capable of leading or anchoring institutional rounds. Founders building generalist healthcare software without clinical or therapeutic content will find less alignment.